ReviewBioelectronic medicine2026
Accelerating the development of bioelectronic medicine: overview and impact of the NIH Stimulating Peripheral Activity to Relieve Conditions (SPARC) initiative.
Review in Bioelectronic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The National Institutes of Health (NIH) Common Fund supports bold scientific programs that catalyze discovery across all biomedical and behavioral research to address high priority challenges for the NIH as a whole and make a broader impact in the scientific community. In 2015, the NIH Common Fund established the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. This program's overall goal was to accelerate the development of neuromodulation, a field of study that uses bioelectronic devices to deliver electrical current to nervous system tissues to produce therapeutic effects in patients. Because the nervous system impacts all bodily functions, neuromodulation therapies have the potential to treat a variety of health conditions by regulating nerves that innervate affected bodily tissues and organs, with high specificity and few side effects. The SPARC program aimed to capitalize on recent advances in technology to deliver detailed, integrated functional and anatomical neural circuit maps for organs and to provide the necessary scientific foundation for clinical translation of more effective and advanced neuromodulation devices and stimulation protocols. Here we outline the SPARC program's contribution to the field of neuromodulation over the past ten years, laying a comprehensive foundation of knowledge to inspire future research and accelerate translation. We discuss the reasoning behind the formation of the program, its structure, and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.